Answers are grounded in this paper and cite their sources.
Discovery identifies potent A1 receptor-selective agonists in human and rat models, suggesting their utility in research.
A series of benzyloxy and phenoxy derivatives of the adenosine receptor agonists N 6 -cyclopentyl adenosine (CPA) and N 6 -cyclopentyl 5-N-ethylcarboxamidoadenosine (CP-NECA) were synthesized, and their potency and selectivity were assessed. We observed that the most potent were the compounds with a halogen in the meta position on the aromatic ring of the benzyloxy-or phenoxycyclopentyl substituent. In general, the NECA-based compounds displayed greater A 1 R selectivity than the adenosine-based compounds, with N 6 -2-(3-bromobenzyloxy)cyclopentyl-NECA and N 6 -2-(3-methoxyphenoxy)cyclopentyl-NECA showing 1500fold improved A 1 R selectivity compared to NECA. In addition, we quantified the compounds' affinity and kinetics of binding at both human and rat A 1 R using a NanoBRET binding assay and found that the halogen substituent in the benzyloxy-or phenoxycyclopentyl moiety seems to confer high affinity for the A 1 R. Molecular modeling studies suggested a hydrophobic subpocket as contributing to the A 1 R selectivity displayed. We believe that the identified selective potent A 1 R agonists are valuable tool compounds for adenosine receptor research.
No takes yet. Share an insight, caveat, or question.
Preti et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: